A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Trial Profile

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PHOTON-2
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Oct 2016 Results of a phylogenetic analysis from this and 10 other phase III Sofosbuvir trials, published in the Clinical Infectious Diseases.
    • 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top